A share price of BeiGene Ltd ADR [BGNE] is currently trading at $205.75, down -4.30%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BGNE shares have gain 8.00% over the last week, with a monthly amount glided 1.53%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
BeiGene Ltd ADR [NASDAQ: BGNE] stock has seen the most recent analyst activity on September 18, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $288. On September 12, 2023, Macquarie initiated with a Outperform rating and assigned a price target of $259 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $287 on August 17, 2023. Citigroup initiated its recommendation with a Buy and recommended $275 as its price target on July 17, 2023. Bernstein downgraded its rating to Mkt Perform for this stock on June 30, 2023, and downed its price target to $196. In a note dated January 12, 2023, Daiwa Securities initiated an Buy rating and provided a target price of $308 on this stock.
BeiGene Ltd ADR experienced fluctuations in its stock price throughout the past year between $126.97 and $248.16. Currently, Wall Street analysts expect the stock to reach $258 within the next 12 months. BeiGene Ltd ADR [NASDAQ: BGNE] shares were valued at $205.75 at the most recent close of the market. An investor can expect a potential return of 25.39% based on the average BGNE price forecast.
Analyzing the BGNE fundamentals
Trailing Twelve Months sales for BeiGene Ltd ADR [NASDAQ:BGNE] were 3.32B which represents 28.20% growth. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.26%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.25 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 198.26 points at the first support level, and at 190.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 214.99, and for the 2nd resistance point, it is at 224.22.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BeiGene Ltd ADR [NASDAQ:BGNE] is 1.93. In addition, the Quick Ratio stands at 1.72 and the Cash Ratio stands at 1.33. Considering the valuation of this stock, the price to sales ratio is 6.04, the price to book ratio is 6.38.
Transactions by insiders
Recent insider trading involved HHLR Advisors, Ltd. (1), Shareholder (1), that happened on Dec 02 ’24 when 1.37 million shares were purchased. Chair, Scientific Advisory Brd, Wang Xiaodong completed a deal on Nov 26 ’24 to sell 40468.0 shares. Meanwhile, Chair, Scientific Advisory Brd Wang Xiaodong sold 7883.0 shares on Nov 26 ’24.
